Fundraising Fox
Starton Therapeutics
Paramus, US · British Columbia, Canada corporation
Find your way into Starton Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
89 people can intro you to Scott
Ask Damian Finio to introduce you to Scott Kahn
You →Damian · together at Phibro Animal Health →Scott
Sign up to find every way you can get introduced to Starton Therapeutics
- Your email: who you already know at Starton Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Starton Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Starton Therapeutics is a clinical-stage biotechnology company that reformulates FDA-approved drugs using proprietary controlled delivery systems to improve their pharmacokinetic profiles. It develops subcutaneous, oral, and transdermal delivery methods aimed at achieving better outcomes in existing or new indications.
Founders & leadership
PL
Pedro Lichtinger WaismanFounder
SK
Scott KahnChief Financial OfficerScott Kahn is an executive with experience in financial leadership across Fortune 500 companies and startups, including roles involving IPO processes and process improvement initiatives.
JO
Jamie OliverExecutive
Board
NK
Nitin KaushalBoard director
MH
Mohamad HusseinBoard director
EB
Eric BaumBoard of Directors; Compensation Committee Chairman, Member of Audit CommitteeCo-Founder & Partner at Solidea Capital
RW
Roy WaldronBoard director
AC
Asher Chanan-KhanBoard director
KA
Kenneth AndersonBoard director
MD
Moses DodoBoard director
FP
Fotios PlakogiannisBoard director
Reported raises · per SEC filings
Form D private placements$10.7M disclosed across 9 rounds · 2018–2024
▶$2.1MraisedOct 2024 · 16 investors · BiotechnologyRule 506(b)
▶$2.1MraisedOct 2024 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott KahnExecutive Officer
- Nitin KaushalDirector
- Mohamad HusseinDirector
- Eric BaumDirector
- Roy WaldronDirector
- Asher Chanan-KhanDirector
- Pedro Lichtinger WaismanExecutive Officer, Director
- Kenneth AndersonDirector
- Moses DodoDirector
- Fotios PlakogiannisDirector
- Jamie OliverExecutive Officer
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- First sale
- Oct 2024
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$970.9KraisedOct 2023 · 8 investors · BiotechnologyRule 506(b)
▶$970.9KraisedOct 2023 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mohamad HusseinDirector
- Jamie OliverExecutive Officer
- Moses DodoDirector
- Scott KahnExecutive Officer
- Pedro Lichtinger WaismanExecutive Officer, Director
- Fotios PlakogiannisDirector
- Nitin KaushalDirector
- Roy WaldronDirector
- Kenneth AndersonDirector
- Asher Chanan-KhanDirector
- Eric BaumDirector
- Offering amount
- $970.9K
- Amount sold
- $970.9K
- First sale
- Oct 2023
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$1.4MraisedApr 2023 · 7 investors · BiotechnologyRule 506(b)
▶$1.4MraisedApr 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mohamad HusseinDirector
- Jamie OliverExecutive Officer
- Moses DodoDirector
- Kenneth AndersonDirector
- Fotios PlakogiannisDirector
- Roy WaldronDirector
- Pedro Lichtinger WaismanExecutive Officer, Director
- Asher Chanan-KhanDirector
- Scott KahnExecutive Officer
- Eric BaumDirector
- Nitin KaushalDirector
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- First sale
- Mar 2023
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$1MraisedJan 2023 · 11 investors · BiotechnologyRule 506(b)
▶$1MraisedJan 2023 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fotios PlakogiannisDirector
- Nitin KaushalDirector
- Jamie OliverExecutive Officer
- Moses DodoDirector
- Asher Chanan-KhanDirector
- Roy WaldronDirector
- Pedro Lichtinger WaismanExecutive Officer, Director
- Cidnee VaykovichExecutive Officer
- Eric BaumDirector
- Mohamad HusseinDirector
- Kenneth AndersonDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Jan 2023
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$1.1MraisedFeb 2022 · 9 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedFeb 2022 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth AndersonDirector
- Keith DarraghExecutive Officer
- Fotios PlakogiannisDirector
- Eric BaumDirector
- Cidnee VaykovichExecutive Officer, Director
- Roy WaldronDirector
- Asher Chanan-KhanDirector
- Mohamad HusseinDirector
- Pedro WaismanExecutive Officer, Director
- Nitin KaushalDirector
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Feb 2022
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$1.1MraisedNov 2021 · 39 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedNov 2021 · 39 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric BaumDirector
- Pedro WaismanExecutive Officer, Director
- Cidnee VaykovichExecutive Officer, Director
- Keith DarraghExecutive Officer
- Fotios PlakogiannisDirector
- Mohamad HusseinDirector
- Roy WaldronDirector
- Asher Chanan-KhanDirector
- Kenneth AndersonDirector
- Nitin KaushalDirector
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Oct 2021
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$77.6KraisedMay 2021 · 5 investors · BiotechnologyRule 506(b)
▶$77.6KraisedMay 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PEDRO LICHTINGERExecutive Officer, Director
- KENNETH ANDERSONDirector
- MOHAMAD HUSSEINDirector
- FOTIOS PLAKOGIANNISDirector
- KEITH DARRAGHExecutive Officer
- ERIC BAUMDirector
- CIDNEE VAYKOVICHExecutive Officer
- LITSA PERPERIDISPromoter
- ROY WALDRONDirector
- NITIN KAUSHALDirector
- Offering amount
- $77.6K
- Amount sold
- $77.6K
- First sale
- Mar 2021
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$2MraisedJan 2020 · 25 investors · Other Health CareRule 506(b)
▶$2MraisedJan 2020 · 25 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- ROY WALDONDirector
- MOHAMAD HUSSEINDirector
- ERIC BAUMDirector
- CIDNEE VAYKOVICHDirector
- NITIN KAUSHALDirector
- ROMAN ROGOLDirector
- PEDRO LICHTINGERExecutive Officer, Director
- FOTIOS PLAKOGIANNISDirector
- Amount sold
- $2M
- Finders' fees
- $161.5K
- First sale
- Dec 2019
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Starton Therapeutics do?
- Starton Therapeutics is a clinical-stage biotechnology company that reformulates FDA-approved drugs using proprietary controlled delivery systems to improve their pharmacokinetic profiles. It develops subcutaneous, oral, and transdermal delivery methods aimed at achieving better outcomes in existing or new indications.
- Who founded Starton Therapeutics?
- Starton Therapeutics was founded by Pedro Lichtinger Waisman.
- How much funding has Starton Therapeutics raised?
- Starton Therapeutics has disclosed $10.7M raised across 9 rounds.
- Where is Starton Therapeutics headquartered?
- Starton Therapeutics is headquartered in Paramus, US.